Abstract:Chronic kidney disease (CKD) is estimated to affect 10-14% of global population. Kidney fibrosis, characterized by excessive extracellular matrix deposition leading to scarring, is a hallmark manifestation in different progressive CKD; However, at present no antifibrotic therapies against CKD exist. Kidney fibrosis is identified by tubule atrophy, interstitial chronic inflammation and fibrogenesis, glomerulosclerosis, and vascular rarefaction. Fibrotic niche, where organ fibrosis initiates, is a complex interplay between injured parenchyma (like tubular cells) and multiple non-parenchymal cell lineages (immune and mesenchymal cells) located spatially within scarring areas. Although the mechanisms of kidney fibrosis are complicated due to the kinds of cells involved, with the help of single-cell technology, many key questions have been explored, such as what kind of renal tubules are profibrotic, where myofibroblasts originate, which immune cells are involved, and how cells communicate with each other. In addition, genetics and epigenetics are deeper mechanisms that regulate kidney fibrosis. And the reversible nature of epigenetic changes including DNA methylation, RNA interference, and chromatin remodeling, gives an opportunity to stop or reverse kidney fibrosis by therapeutic strategies. More marketed (e.g., RAS blockage, SGLT2 inhibitors) have been developed to delay CKD progression in recent years. Furthermore, a better understanding of renal fibrosis is also favored to discover biomarkers of fibrotic injury. In the review, we update recent advances in the mechanism of renal fibrosis and summarize novel biomarkers and antifibrotic treatment for CKD.

Cellular senescence and the senescence-associated secretory phenotype: Potential therapeutic targets for renal fibrosis

Cellular Senescence in Kidney Fibrosis: Pathologic Significance and Therapeutic Strategies

Cellular Senescence, A Novel Therapeutic Target For Mesenchymal Stem Cells In Acute Kidney Injury

Cellular senescence of renal tubular epithelial cells in renal fibrosis

Renal fibrosis: New insights into the pathogenesis and therapeutics

The emerging role of cellular senescence in renal diseases

The Interaction Between Cellular Senescence and Chronic Kidney Disease As a Therapeutic Opportunity

Emerging Roles Of Long Non-Coding Rnas In Renal Fibrosis

Cellular senescence in acute kidney injury: Target and opportunity

Potential Therapeutic Medicines for Renal Fibrosis: Small-molecule Compounds and Natural Products.

Senescence and tissue fibrosis: opportunities for therapeutic targeting

Targeted Inhibition of Endoplasmic Reticulum Stress: New Hope for Renal Fibrosis

Implication of cellular senescence in the progression of chronic kidney disease and the treatment potencies

The potential role of senescence in limiting fibrosis caused by aging

Kidney Fibrosis: from Mechanisms to Therapeutic Medicines

Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression

New Therapies for the Treatment of Renal Fibrosis.

Targeting Senescent Cells in Fibrosis: Pathology, Paradox, and Practical Considerations

Defining Therapeutic Targets for Renal Fibrosis: Exploiting the Biology of Pathogenesis

Renal Fibrosis: SIRT1 Still of Value

Targeting the Wnt/β-Catenin Signaling Pathway as a Potential Therapeutic Strategy in Renal Tubulointerstitial Fibrosis